Bicara Therapeutics Inc. Common Stock (BCAX) Cash Flow Statement

The OCF/NI ratio has been consistently below 1.0 in most quarters, with 2024Q4 and 2024Q1 showing ratios above 1.0, suggesting timing differences in working capital. The recent quarters show a narrowing gap, implying that accruals are minimal and losses are largely cash-based. This indicates that the reported net losses are a reliable proxy for cash consumption, with no significant non-cash distortions.

The FCF burn has accelerated sharply, particularly in 2026Q2, reflecting increased R&D spending and clinical trial costs. The FCF margin is not meaningful due to zero revenue, but the absolute burn rate is escalating, suggesting that the company is consuming cash at an increasing pace. This trend is consistent with the prior income statement analysis showing R&D escalation, and investors should monitor the runway given the lack of revenue.

Capital expenditures are negligible, totaling less than $0.5M over the period, which is typical for a biotech company outsourcing manufacturing and relying on contract research organizations. This suggests that the primary cash burn is operational, not capital-intensive, and that the company's asset base is not expanding. The low CapEx implies that future growth is dependent on successful clinical outcomes rather than physical capacity.

The working capital changes are erratic, with positive contributions in recent quarters offsetting earlier negative swings. This volatility likely reflects the timing of payments to CROs and other vendors, as well as prepaid expenses. The positive working capital changes in 2026Q1 and Q2 suggest that the company is managing payables and receivables to conserve cash, but the overall impact is minor relative to the operating burn.

The company has not returned any capital to shareholders, which is expected for a clinical-stage biotech. The absence of capital deployment activities indicates that all available cash is being funneled into R&D and operations. This is consistent with a pre-revenue company prioritizing pipeline advancement over shareholder returns, and investors should expect continued dilution or debt financing to fund operations.

The cumulative gap between net income and operating cash flow is only $54.2M, which is relatively small given the scale of losses. This suggests that the reported losses are largely cash-based, with minimal non-cash accruals. The divergence is primarily due to stock-based compensation and working capital timing, but the overall alignment indicates that the company is not using aggressive accounting to mask cash burn. Investors should note that the cash burn is real and accelerating.